- Home
- JBGS vs NBTX Comparison
JBGS vs NBTX Comparison
Compare JBGS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | NBTX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | JBGS | NBTX |
|---|---|---|
| Price | $14.98 | $28.70 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 496.3K | 45.0K |
| Earning Date | 04-28-2026 | 03-17-2026 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.28 | $2.99 |
| 52 Week High | $24.30 | $41.89 |
Technical Indicators
Market Signals| Indicator | JBGS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 47.16 |
| Support Level | $14.21 | $20.11 |
| Resistance Level | $15.95 | $30.23 |
| Average True Range (ATR) | 0.46 | 2.61 |
| MACD | 0.06 | -0.76 |
| Stochastic Oscillator | 79.58 | 1.93 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.